Non-T cell depletion haploidentical hematopoietic stem-cell transplantation for T lymphoblastic lymphoma

( views:221, downloads:0 )
Author:
HE Xue-feng(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
WU De-pei(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
SUN Ai-ning(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
ZHANG Xiang(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
QIU Hui-ying(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
HAN Yue(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
TANG Xiao-wen(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
FU Cheng-cheng(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
JIN Zheng-ming(Jiangsu Institute of Hematology, First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 20, Issue 08, 2011
DOI:
10.3760/cma.j.issn.1009-9921.2011.08.005
Key Word:
Lymphoma, lymphoblastic;Haploidentical bone marrow transplantation;Myeloablative therapy;T-cell depletion

Abstract: Objective To explore the efficacy of non-T cell depletion haploidentical hematopoietic stem-cell transplantation for T lymphoblastic lymphoma (T-LL). Methods 3 T-LL patients achieving complete remission received haploidentical bone marrow stem cell transplantation with granulocyte-colony-stimulating factor (G-CSF) mobilized bone marrow grafts from related donor without T-cell depletion. Two of them received a myeloablative conditioning regimen consisting of high-doses of cyclophosphamide and cytarabine with total body irradiation, whereas the other was preconditioned with busulfan, cyclophosphamide and cytarabine. All patients received strengthened phophylaxis regimen including rabbit anti-thymocyte globulin against acute graft-versus-host disease. Results All patients had rapid hematopoietic engraftment with the median time for neutrophil and platelet recovery being 12 days and 13 days, respectively. They are still alive without relapse at a median follow-up of 24 months (range: 9-75 months). Conclusion Treatment related toxicity can be acceptable in non-T cell depletion haploidenfical hematopoietic stem-cell transplantation for T-LL and the patients may achieve long term survival.

  • [1]Goldman FD,Rumelhart SL,Dealacron P,et al.Poor outcome in children with refractory/relapsed leukemia undergoing bone marrow transplantation with mismatched family member donors.Bone Marrow Transplant,2000,25:943-948.
  • [2]Kurokawa T,Ishiyama K,Ozaki J,et al.Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies:analysis of 66 cases at a single Japanese center.Int J Hematol,2010,91:661-669.
  • [3]黄晓军,刘代红.人类白细胞抗原不合或单倍体亲属供者造血干细胞移植.临床内科杂志,2006,23:581-584.
  • [4]The Non-Hodgkin's Lymphoma Classification Project.A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.Blood,1997,89:3909-3918.
  • [5]Ractz EA,Perkins SL,Bhojwani D,et al.Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Pediatr Blood Cancer,2006,47:130-140.
  • [6]Le Gouill S,Lepretre S,Briere J,et al.Adult lymphoblastic lymphoma:a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials.Leukemia,2003,17:2220-2224.
  • [7]王沁,周红,江志生.T淋巴母细胞淋巴瘤的治疗方案选择.白血病·淋巴瘤,2004,13:303-305.
  • [8]Levine JE,Harris RE,Loberiza FJ,et al.A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.Blood,2003,101:2476-2482.
  • [9]Peniket A J,Ruiz DEM,Taghipour G,et al.An EBMT registry matched study of allogeneic stem cell transplants for lymphoma:allegeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.Bone Marrow Transplant,2003,31:667-678.
  • [10]Song KW,Barnett MJ,Gascoyne RD,et al.Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.Ann Oncol,2007,18:535-540.
  • [11]Ikegame K,Tanji Y,Kitai N,et al.Successful treatment of refractory T-cell acute lymphoblastc leukemia by unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical)sibling.Bone Marrow Transplant,2003,31:507-510.
  • [12]Zhou Y,Huang W,Li H,et al.Unmanipulated haploidentical peripheral blood stem cell transplantation for precursor T-cell lymphoblastic lymphoma relapsed after autologous PBSCT.J Pediatr Hematol Oncol,2011,33:224-226.
  • [13]Ciceri F,Labopin M,Aversa F,et al.A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia:a risk factor analysis of outcomes for patients in remission at transplantation.Blood,2008,112:3574-3581.
  • [14]Aversa F,Reisner Y,Martelli MF.The haploidentical option for highrisk haematological malignancies.Blood Cells Mol Dis,2008,40:8-12.
  • [15]Ichinohe T,Teshima T,Matsuoka K,et al.Fetal-maternal microchimerism:impact on hematopoietic stem cell transplantation.Curr Opin lmmunol,2005,17:546-552.
  • [16]Huang XJ,Liu DH,Liu KY,et al.Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.Bone Marrow Transplant,2006,38:291-297.
  • [17]Lacorcia G,Swistak M,Lawendowski C,et al.Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion.Transplantation,2009,87:966-974.
  • [18]Rachamim N,Gan J,Segall H,et al.Tolerance induction by "megadose" hematopoietic transplants:donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture.Transplantation,1998,65:1386-1393.
  • [19]Ji S,Chen H,Wang H,et al.Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.Chin Med J (Engl),2001,114:191-195.
  • [20]Morton J,Hutchins C,Durrant S.Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow:significantly less graftversus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.Blood,2001,98:3186-3191.
  • [21]Tallman M S,Rowlings P A,Milone G,et al.Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission.Blood,2000,96:1254-1258.
  • [22]Ma X,Wu D,Sun A,et al.The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.Am J Hematol,2010,85:141-142.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn